Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. - Wikidata - awgldk - TriplyDB

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

http://www.wikidata.org/entity/Q40109415

about

Changing strategies for target therapy in gastric cancer Current treatment of early breast cancer: adjuvant and neoadjuvant therapy The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Trastuzumab emtansine: mechanisms of action and drug resistance Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings.A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.Primary trastuzumab resistance: new tricks for an old drug.The emerging importance of α-L-fucose in human breast cancer: a review.Mild hyperthermia influence on Herceptin(®) properties.CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer A common glycan structure on immunoglobulin G for enhancement of effector functions Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan.Resistance to Trastuzumab in Breast Cancer.Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells.Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.Models for prevention and treatment of cancer: problems vs promises.Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D.

P2860

Q26774513-750345B4-DF32-454A-86C2-088D197C6D99 Q27011658-37DA1511-4B6C-47DD-B35F-CD97693DEF18 Q28543104-D77FBD0F-3FD1-42FB-A703-0DD8F12EA93A Q33658544-40230475-086E-4186-815B-CDB55041C89B Q33660069-79ABCC2F-C54D-447E-A342-C5702D1A45CB Q33712476-EEF390F3-61C5-48B8-83E6-B0F9ED88B13A Q33737278-B4F667A2-B9C7-493B-BC26-663572F6F15F Q33759627-4772C26C-1E93-475A-8350-3F5C43521E7D Q33816185-61788C2F-F998-44FB-9768-3D7C4FF1A446 Q33833475-9803DB34-2468-4076-873E-FF622714A8E1 Q34082392-8762C4F9-9EA9-4E93-ADF0-269375A2149A Q34221898-79DF48C8-8929-4F4C-A796-BAF4913B49F9 Q34355748-1314109F-C45B-4A3D-A997-A5B569339A8E Q34382125-F7F4C022-7227-4BA8-8629-967AF4A06C72 Q34475414-574379CB-D971-405F-84A6-373FC8168CC4 Q34610251-E6ED7DB5-FA97-4E28-BDD3-380554669B16 Q35172546-C4E581A2-064E-4453-8941-B18ED424BEA3 Q35184811-81C8FF28-BCC2-4822-8685-CD5DDC42CD0D Q35546950-B2383E0F-1C2B-4BAD-B620-9B618CAF6DF9 Q35559041-F2E5494D-C31F-45D3-A00A-07FDA769AC48 Q35569418-A32FD99D-3CF4-48C0-8294-71E125A2E58F Q35684440-ED04C462-A5EB-4D4F-AA88-601B7EB3556C Q35733827-9A98E2E7-EF2B-47D6-A68A-82260A1ECC31 Q35909554-038F760D-EE77-4D7B-837A-3F1940652CC4 Q35948050-669A4D8B-C048-4466-9927-21EFAFEE2C31 Q35977527-44B2E046-8066-40BF-BD34-6D99F92D9DCB Q36008257-544DB35F-E0FE-4AD6-ADFD-8BC50F166529 Q36114852-1DBDBC44-F9AB-46AB-86BA-4F4DBF5E608E Q36285897-79BAA414-7110-4E8A-BBD9-85F2CD5DB1E8 Q36318226-9637A991-C56C-402F-912C-BAEC0D80183A Q36373337-AC857963-B112-44BF-A5F0-8853FDBB4803 Q36440625-B98404DF-5936-43AB-8DE8-B0BB06362628 Q36758890-9A64DA8B-BF31-4FF8-9238-C35A21ADCCDA Q36843741-D0FFF81D-66E1-49DE-AF93-41F9C4321832 Q36847220-1AE6728F-20AF-45AB-A443-5892C2192AEE Q37111104-2F0B044E-7EBF-4E32-A49C-09D2544ACE3D Q37327307-1E359553-3343-45A0-8D99-A9F69DA40E60 Q37356273-636FA4CC-FA43-4D5E-8D2A-3CED635794A0 Q37360367-593C5DCB-17FC-4945-9448-B066A73227C6 Q37520544-CAE1361F-0425-4857-9074-ABBD11056540

P2860

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

http://www.wikidata.org/entity/Q40109415

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Trastuzumab causes antibody-de ...... ite intrinsic drug resistance.

@en

type

label

Trastuzumab causes antibody-de ...... ite intrinsic drug resistance.

@en

prefLabel

Trastuzumab causes antibody-de ...... ite intrinsic drug resistance.

@en

P1433

Q40109415-D6B16B71-0E67-4BE8-9744-68ED2DA84B18

P1476

Q40109415-C5F1D3AA-E0AD-4429-B113-AD4F8F2431D3

P2093

Q40109415-1892AA92-2CB3-4BC3-B0E7-5D85C6DC7D02

Q40109415-65CCCD6E-8192-4341-83E1-A89E04208419

Q40109415-7966BA0B-B07F-4973-BD6A-261F0359B5BD

Q40109415-8B54F90E-7129-4015-A9FA-D7AACDA81D9B

Q40109415-99575380-E2A7-497E-B49E-45A15F26EE32

Q40109415-A898307C-377D-4C8B-A114-8F36A41B7C4D

Q40109415-B28083DB-23DF-4901-813C-D8385B026682

Q40109415-B38FD2A4-6421-44B5-A9CD-28F303881AAE

Q40109415-BEDDD4AD-6AF2-4E52-B6B4-34D818134301

Q40109415-DEF5CB6D-5D8C-4C4D-9CA5-F251DCBC8C6E

P304

Q40109415-4F7DABBA-349B-44F6-BEB1-25FCAA866FE5

P31

Q40109415-BFD68481-FF9F-4AB8-86D7-BB061840C7D9

P356

Q40109415-5162D5C5-8D96-4DEC-A860-3CEA05AD9723

P433

Q40109415-A517CF63-FBC2-4D84-A59E-D4376BB48A42

P478

Q40109415-9BAAA935-3702-4DF1-8F45-44BEEF756034

P50

Q40109415-74805062-04E2-4904-99FD-66437341050F

P577

Q40109415-E8C49DE4-E9BA-4F21-A25A-B6B9CB3E9220

P698

Q40109415-15BE9E03-1747-4399-B759-C3399856F291

P921

Q40109415-394977FE-7B79-4839-A90F-AA4AE606F2B9

Q40109415-BCF1E2EF-0EF5-4CF1-859C-5318E8A92587

Q40109415-C92EE6A6-981E-45A8-BDBA-7D09A8F85C5A

P356

1535-7163.MCT-06-0766

P1433

Molecular Cancer Therapeutics

P1476

Trastuzumab causes antibody-de ...... ite intrinsic drug resistance.

@en

P2093

Anita Kapanen

http://www.w3.org/2001/XMLSchema#string

György Vereb

http://www.w3.org/2001/XMLSchema#string

István Juhász

http://www.w3.org/2001/XMLSchema#string

Jorma Isola

http://www.w3.org/2001/XMLSchema#string

János Szöllösi

http://www.w3.org/2001/XMLSchema#string

Minna Tanner

http://www.w3.org/2001/XMLSchema#string

Márk Barok

http://www.w3.org/2001/XMLSchema#string

Päivikki Kauraniemi

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Pályi-Krekk

http://www.w3.org/2001/XMLSchema#string

P304

2065-2072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-06-0766

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17620435

http://www.w3.org/2001/XMLSchema#string

P921